

Non-Small Cell Lung Cancer Market by Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Others and Adenocarcinoma), Treatment Type (Chemotherapy, Targeted Therapy and Immunotherapy), Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy and Online Pharmacy) and Geography (North America, Europe, APAC and RoW) - Forecast up to 2027

<https://marketpublishers.com/r/N6927241A0C2EN.html>

Date: July 2023

Pages: 223

Price: US\$ 4,500.00 (Single User License)

ID: N6927241A0C2EN

Abstracts

Non-small cell lung cancer is a form of lung cancer, where malignant tumor cells are formed in the lungs. It comprises of a group of different diseases, which behave same as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

Adenocarcinoma is a form of non-small cell lung cancer, which is most usual in women than men and more in young people than old age group of people. The non small cell lung cancer market growth is significantly propelled by surge in the rate of consumption of tobacco more by young group of population, extreme air pollution, and unhealthy lifestyle. Exposure to air comprising traces of metals such as arsenic, asbestos, and others, are key reasons of adenocarcinoma. Therefore, the surge in number of people smoking and following unhealthy lifestyle are few of the leading factors causing non-small cell lung cancer. However, the limited number of skilled professionals will hamper the market growth. The Non-Small Cell Lung Cancer Market is likely to grow at a rate of 9.2% CAGR by 2027.

Non-Small Cell Lung Cancer Market based on Type

Squamous Cell Carcinoma

Large Cell Carcinoma

Others

Adenocarcinoma

Non-Small Cell Lung Cancer Market based on Treatment Type

Chemotherapy

Targeted Therapy

Immunotherapy

Non-Small Cell Lung Cancer Market based on Distribution Channel

Hospital Pharmacy

Drug Store and Retail Pharmacy

Online Pharmacy

Non-Small Cell Lung Cancer Market based on Geography

North America

Europe

Asia Pacific

Rest of the World

On the basis of type the market is divided into Squamous Cell Carcinoma, Large Cell Carcinoma, Others and Adenocarcinoma. In this segmentation, the Adenocarcinoma segment holds the largest share in the non-small cell lung cancer market. The largest share of the segment is ascribed to the high number of people affected by adenocarcinoma and availability of wide range of treatments for this indication.

In terms of treatment type, the non-small cell lung cancer market is majorly segmented into Chemotherapy, Targeted Therapy and Immunotherapy. Among them the targeted therapy category holds the significant share in market. This is due to the specific clinical benefits which this therapy provides, such as low risk of negative effects and the availability of various targeted medicines. Also, more patients are choosing targeted therapy as a cancer treatment option because it is effective in up to 80% of cases.

In terms of distribution channel, the market is categorized into Hospital Pharmacy, Drug Store and Retail Pharmacy and Online Pharmacy. The Hospital Pharmacy segment is likely to have a maximum share in the market growth. This can accredited to the surge

in the number of NSCLC patients being admitted to hospitals and the availability of qualified specialists in these settings.

Based on the geographical analysis the non-small cell lung cancer market is segregated into North America, Europe, Asia Pacific and Rest of the World. The North America region is anticipated to have the maximum share in the market. This is because of region's robust concentration of key companies, well-developed healthcare infrastructure, and increased public awareness of the significance of early cancer detection.

Furthermore, the global rise in the cancer cases fuels the global non-small cell lung cancer market over the estimated period. As per the American Cancer Society statistics from 2016, the majority of cases of SCLC occur in people between the ages of 60 and 80, with a worldwide death rate of 30,000 per year. Additionally, as per the WHO data, lung cancer is the second most common type of cancer in men and women, accounting for 1.59 million deaths. This fuels the global market growth.

The leading players of the market are F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., AstraZeneca, Celgene Corporation, Sanofi, and boehringer ingelheim

As a result, smoking is the most common habit in the present scenario around the world which is the significant reason for all types of lung cancer. Specifically, smoking is the major reason for non-small cell lung cancer which enhances the scope of the present market.

The report analyzes the geographical highlights in terms of consumption of the product/service within the region also indicates the factors which are affecting the market within each region.

The report consists of opportunities and challenges faced by the players in the global non-small cell lung cancer

The report implies the regional and segmental analysis which is projected to witness the fastest growth.

Provides competitive outlook which includes the market ranking of the key players, coupled with new product launches, partnerships, business expansions, and acquisitions.

Contents

1. EXECUTIVE SUMMARY

2. INDUSTRY OUTLOOK

2.1. Industry Overview

2.2. Industry Trends

3. MARKET SNAPSHOT

3.1. Market Definition

3.2. Market Outlook

3.2.1. Porter Five Forces

3.3. Related Markets

4. MARKET CHARACTERISTICS

4.1. Market Overview

4.2. Market Segmentation

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. DRO - Impact Analysis

5. TYPE: MARKET SIZE & ANALYSIS

5.1. Overview

5.2. Squamous Cell Carcinoma

5.3. Large Cell Carcinoma

5.4. Others

5.5. Adenocarcinoma

6. TREATMENT TYPE: MARKET SIZE & ANALYSIS

6.1. Overview

6.2. Chemotherapy

6.3. Targeted Therapy

6.4. Immunotherapy

7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS

7.1. Overview

7.2. Hospital Pharmacy

7.3. Drug Store and Retail Pharmacy

7.4. Online Pharmacy

8. GEOGRAPHY: MARKET SIZE & ANALYSIS

8.1. Overview

8.2. North America

8.3. Europe

8.4. Asia Pacific

8.5. Rest of the World

9. COMPETITIVE LANDSCAPE

9.1. Competitor Comparison Analysis

9.2. Market Developments

9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships

9.2.2. Product Launches and execution

10. VENDOR PROFILES

10.1. F. Hoffmann-La Roche Ltd

10.1.1. Overview

10.1.2. Financial Overview

10.1.3. Product Offerings

10.1.4. Developments

10.1.5. Business Strategy

10.2. Eli Lilly and Company

10.2.1. Overview

10.2.2. Financial Overview

10.2.3. Product Offerings

10.2.4. Developments

10.2.5. Business Strategy

10.3. Bristol-Myers Squibb Company

- 10.3.1. Overview
- 10.3.2. Financial Overview
- 10.3.3. Product Offerings
- 10.3.4. Developments
- 10.3.5. Business Strategy
- 10.4. Merck & Co., Inc.
 - 10.4.1. Overview
 - 10.4.2. Financial Overview
 - 10.4.3. Product Offerings
 - 10.4.4. Developments
 - 10.4.5. Business Strategy
- 10.5. Novartis AG
 - 10.5.1. Overview
 - 10.5.2. Financial Overview
 - 10.5.3. Product Offerings
 - 10.5.4. Developments
 - 10.5.5. Business Strategy
- 10.6. Pfizer Inc.
 - 10.6.1. Overview
 - 10.6.2. Financial Overview
 - 10.6.3. Product Offerings
 - 10.6.4. Developments
 - 10.6.5. Business Strategy
- 10.7. Astrazeneca
 - 10.7.1. Overview
 - 10.7.2. Financial Overview
 - 10.7.3. Product Offerings
 - 10.7.4. Developments
 - 10.7.5. Business Strategy
- 10.8. Celgene Corporation
 - 10.8.1. Overview
 - 10.8.2. Financial Overview
 - 10.8.3. Product Offerings
 - 10.8.4. Developments
 - 10.8.5. Business Strategy
- 10.9. Sanofi
 - 10.9.1. Overview
 - 10.9.2. Financial Overview
 - 10.9.3. Product Offerings

- 10.9.4. Developments
- 10.9.5. Business Strategy
- 10.10. boehringer ingelheim
 - 10.10.1. Overview
 - 10.10.2. Financial Overview
 - 10.10.3. Product Offerings
 - 10.10.4. Developments
 - 10.10.5. Business Strategy

11. ANALYST OPINION

12. ANNEXURE

- 12.1. Report Scope
- 12.2. Market Definitions
- 12.3. Research Methodology
 - 12.3.1. Data Collation and In-house Estimation
 - 12.3.2. Market Triangulation
 - 12.3.3. Forecasting
- 12.4. Report Assumptions
- 12.5. Declarations
- 12.6. Stakeholders
- 12.7. Abbreviations

List Of Tables

LIST OF TABLES

TABLE 1. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 2. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR SQUAMOUS CELL CARCINOMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR LARGE CELL CARCINOMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR ADENOCARCINOMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 7. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR CHEMOTHERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 8. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR TARGETED THERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR IMMUNOTHERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 10. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 11. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR HOSPITAL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 12. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR DRUG STORE AND RETAIL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 13. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR ONLINE PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 14. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 15. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 16. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 17. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 18. U.S NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 19. U.S NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 20. U.S NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 21. CANADA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 22. CANADA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 23. CANADA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 24. EUROPE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 25. EUROPE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 26. EUROPE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 27. EUROPE NON-SMALL CELL LUNG CANCER MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 28. GERMANY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 29. GERMANY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 30. GERMANY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 31. U.K NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 32. U.K NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 33. U.K NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 34. FRANCE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 35. FRANCE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 36. FRANCE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 37. ITALY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE,

2021-2027 (USD BILLION)

TABLE 38. ITALY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 39. ITALY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 40. SPAIN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 41. SPAIN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 42. SPAIN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 43. ROE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 44. ROE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 45. ROE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 46. ASIA PACIFIC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 47. ASIA PACIFIC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 48. ASIA PACIFIC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 49. ASIA PACIFIC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 50. CHINA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 51. CHINA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 52. CHINA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 53. INDIA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 54. INDIA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 55. INDIA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 56. JAPAN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 57. JAPAN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 58. JAPAN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 59. REST OF APAC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 60. REST OF APAC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 61. REST OF APAC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 62. REST OF WORLD NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 63. REST OF WORLD NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 64. REST OF WORLD NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 65. F. HOFFMANN-LA ROCHE LTD: FINANCIALS

TABLE 66. F. HOFFMANN-LA ROCHE LTD: PRODUCTS & SERVICES

TABLE 67. F. HOFFMANN-LA ROCHE LTD: RECENT DEVELOPMENTS

TABLE 68. ELI LILLY AND COMPANY: FINANCIALS

TABLE 69. ELI LILLY AND COMPANY: PRODUCTS & SERVICES

TABLE 70. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS

TABLE 71. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS

TABLE 72. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES

TABLE 73. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS

TABLE 74. MERCK & CO., INC.: FINANCIALS

TABLE 75. MERCK & CO., INC.: PRODUCTS & SERVICES

TABLE 76. MERCK & CO., INC.: RECENT DEVELOPMENTS

TABLE 77. NOVARTIS AG: FINANCIALS

TABLE 78. NOVARTIS AG: PRODUCTS & SERVICES

TABLE 79. NOVARTIS AG: RECENT DEVELOPMENTS

TABLE 80. PFIZER INC.: FINANCIALS

TABLE 81. PFIZER INC.: PRODUCTS & SERVICES

TABLE 82. PFIZER INC.: RECENT DEVELOPMENTS

TABLE 83. ASTRAZENECA: FINANCIALS

TABLE 84. ASTRAZENECA: PRODUCTS & SERVICES

TABLE 85. ASTRAZENECA: RECENT DEVELOPMENTS

TABLE 86. CELGENE CORPORATION: FINANCIALS

TABLE 87. CELGENE CORPORATION: PRODUCTS & SERVICES

TABLE 88. CELGENE CORPORATION: RECENT DEVELOPMENTS

TABLE 89. SANOFI: FINANCIALS

TABLE 90. SANOFI: PRODUCTS & SERVICES

TABLE 91. SANOFI: RECENT DEVELOPMENTS

TABLE 92. BOEHRINGER INGELHEIM: FINANCIALS

TABLE 93. BOEHRINGER INGELHEIM: PRODUCTS & SERVICES

TABLE 94. BOEHRINGER INGELHEIM: RECENT DEVELOPMENTS

I would like to order

Product name: Non-Small Cell Lung Cancer Market by Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Others and Adenocarcinoma), Treatment Type (Chemotherapy, Targeted Therapy and Immunotherapy), Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy and Online Pharmacy) and Geography (North America, Europe, APAC and RoW) - Forecast up to 2027

Product link: <https://marketpublishers.com/r/N6927241A0C2EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N6927241A0C2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970